Fundraising FoxARCH Venture Partners — 2017 Investments
7 investments dated 2017 · listed companies and verified rows first · show all
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in
Board seatKristina Burow· per SEC Form D · $47M raise · filed Jan 2018
Co-investorsSamsara BioCapitalEcoR1 CapitalPolaris Partners
Seattle 'scientific wellness' startup that paired genetic, blood and microbiome testing with health coaching; closed in 2019.
HealthtechSeattle, US
Nathan Price(Director)Clayton Lewis(Executive Officer, Director)
BoardTim Kilgallon(Director)
Board seatRobert Nelsen· per SEC Form D · $30M raise · filed Jun 2017
Co-investorsCorewell Health VenturesPolaris Partners
Westlake Village dermatology company developing late-stage topical and photoparticle skin treatments; assets sold to Sebacia in 2020.
BiotechWeslake Village, US
Frederick C. Beddingfield III(Executive Officer, Director)Todd Harris(Director, Executive Officer)inDiane Stroehmann(Executive Officer)inPaul F. Lizzul(Executive Officer)inRic Peterson(Executive Officer)inTimothy K. Andrews(Executive Officer)
Board seatRobert NelsenKristina Burow· per SEC Form D · $40.5M raise · filed May 2017
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesOUP (Osage University Partners)AlexandriaDeerfield Management CompanyFidelity InvestmentsHBM Healthcare Investments+5 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.